间质性肺病合并肺动脉高压患者肺移植机会增加
单中心回顾性研究比较了2010至2016年间50例间质性肺病合并继发性肺动脉高压患者以静脉-静脉(VV)或静脉-动脉(VA)体外膜肺氧合(ECMO)桥接肺移植的生存至移植情况。初始VA ECMO较初始VV ECMO的生存至移植显著更高(p=0.03),VA较VV死亡风险降低59%(风险降低0.41,95%CI:0.18至0.92,p=0.03)。ECMO上行走与死亡风险降低80%相关(风险降低0.20,95%CI:0.08至0.48,p<0.01)。
要点
- 初始VA ECMO较初始VV ECMO的生存至移植显著更高(p=0.03)。
- VA较VV ECMO死亡风险降低59%(风险降低0.41,95%CI:0.18至0.92,p=0.03)。
- ECMO上行走与死亡风险降低80%相关(风险降低0.20,95%CI:0.08至0.48,p<0.01)。
核心结论
- 对于终末期间质性肺病合并肺动脉高压患者,静脉-动脉(VA)ECMO上半身配置显著改善总体生存至移植。
研究设计与样本
- 单中心回顾性综述,纳入2010至2016年间以VV或VA ECMO桥接肺移植的间质性肺病合并继发性肺动脉高压患者。
- 共50例患者,初始接受VV ECMO者19例,初始接受VA ECMO者31例。
- 采用Cox比例风险模型比较VV与VA ECMO策略间与生存至移植相关的因素。
- 亚组分析比较维持VV ECMO或转换为VA ECMO的VV ECMO患者。
主要发现
- 初始VA ECMO较初始VV ECMO的生存至移植显著更高(p=0.03)。
- Cox比例风险模型显示VA较VV ECMO死亡风险降低59%(风险降低0.41,95%CI:0.18至0.92,p=0.03)。
- 从VV转换为VA ECMO的患者等待移植期间生存显著长于维持VV ECMO的患者(p=0.03)。
- 移植前在ECMO上行走与死亡风险降低80%相关(风险降低0.20,95%CI:0.08至0.48,p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplantation for end-stage interstitial lung disease (ILD) and pulmonary hypertension (PH) has varying results based on ECMO configuration. We compare our experience using venovenous (VV) and venoarterial (VA) ECMO bridge to transplantation for ILD with PH on survival to successful transplantation. METHODS: A single-center retrospective review was done of patients with ILD and secondary PH who were placed on either VV or VA ECMO as bridge to transplantation from 2010 to 2016. Comparisons for factors associated with survival to transplantation between VV and VA ECMO strategies were made using Cox proportional hazards model. Subgroup analysis included comparisons of VV ECMO patients who remained on VV or were converted to VA ECMO. RESULTS: A total of 50 patients with ILD and PH were treated initially with either VV (n = 19) or VA (n = 31) ECMO as bridge to lung transplantation. Initial VA ECMO had a significantly higher survival to transplantation compared with initial VV ECMO (p = 0.03). Cox proportional hazards modeling showed a 59% reduction in risk of death for VA compared with VV ECMO (hazard reduction 0.41, 95% confidence interval: 0.18 to 0.92, p = 0.03). Patients converted from VV to VA ECMO had significantly longer survival awaiting transplant than patients who remained on VV ECMO (p = 0.03). Ambulation on ECMO before transplantation was associated with an 80% reduction in the risk of death (hazard reduction 0.20, 95% confidence interval: 0.08 to 0.48, p < 0.01). CONCLUSIONS: Venoarterial ECMO upper body configuration for patients with end stage ILD and PH significantly improves overall survival to transplantation.
引用
- Chicotka S, Pedroso FE, Agerstrand CL, et al. Increasing Opportunity for Lung Transplant in Interstitial Lung Disease With Pulmonary Hypertension. Ann Thorac Surg. 2018. PMID: 29852149. doi:10.1016/j.athoracsur.2018.04.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。